Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:33 AM
Ignite Modification Date:
2025-12-25 @ 4:33 AM
NCT ID:
NCT02854618
Eligibility Criteria:
Inclusion Criteria:
* patients eligible for a treatment by everolimus in association with the exemestane
* Performance status of 0,1 or 2 according to the WHO
* Patients affected of a breast cancer advanced and\\or metastatic HER2 negative expressing the hormonal receptor RH +
* menopausal Patients
Exclusion Criteria:
* Psychiatric disease compromising the understanding of the information or the realization of the study
* Vulnerable people according to the law (minors, adults under protection, private persons of freedom)
* Histories of cancer in 5 years preceding the diagnosis (except breast cancer, squamous-cell)
* Not menopausal women
* Unaffiliated people to the Social Security
* People being for the period of exclusion from another study
* Hypersensitivity in the active substance, in the other by-products of the rapamycin or in one of the excipients.
* Symptomatic visceral achievement
* Legal incapacity or limited legal capacity
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Maximum Age:
85 Years
Study:
NCT02854618
Study Brief:
Protocol Section:
NCT02854618